S1 Table. Cox regression analysis of predictive factors according to progression-free survival and overall survival (n=28)

Variable	PFS		OS	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (median) (< 58 yr vs. ≥ 58 yr)	0.869 (0.321-2.352)	0.782	0.656 (0.2-2.151)	0.486
Sex (male vs. female)	0.834 (0.267-2.603)	0.755	1.485 (0.434-5.078)	0.520
Smoking history (no vs. yes)	1.249 (0.458-3.406)	0.664	1.151 (0.351-3.776)	0.816
Histologic type (papillary vs. others)	4.590 (10.49-20.08)	0.098	2.190 (0.259-18.481)	0.298
MSKCC risk group (favorable vs. others)	0.659 (0.148-2.934)	0.421	13.651 (1.201-155.14)	< 0.001
ECOG PS (0 vs. 1)	1.740 (0.603-5.025)	0.306	1.449 (0.423-4.973)	0.555
Previous nephrectomy (no vs. yes)	1.403 (0.397-4.983)	0.598	0.750 (0.197-2.861)	0.674
No. of organ involvement (< 3 vs. ≥ 3)	0.8787 (0.318-2.424)	0.878	1.368 (0.416-4.504)	0.606
Previous systemic therapy (no vs. yes)	0.608 (0.219-1.687)	0.339	1.493 (0.453-4.921)	0.510

PFS, progression free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; MSKCC, Memorial Sloan-Kettering Cancer Center; ECOG PS, Eastern Cooperative Oncology Group performance status.